Double-Punch immunotherapy trial aims to keep stomach cancer at bay after surgery
NCT ID NCT07283848
Summary
This study aimed to test whether adding two immunotherapy drugs (domvanalimab and zimberelimab) to standard chemotherapy could better control cancer in people with operable stomach or esophageal cancer. Patients would have received the drug combination for about 4 months before surgery and for 8 months after recovery. The goal was to see if this approach could prevent the cancer from coming back and improve survival. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA STOMACH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.